1. Sanchez, E, Nava, S, Moran, C, Romero, J, Cebron M. Estado actual de la preeclampsia en Mexico: de lo epidemiológico a sus mecanismos moleculares. Rev Investig Clínica. 2010;62(3):252-260.
2. Organización Mundial de la salud. Mortalidad Materna. Oms. 2014;2:2-5. http://www.who.int/es/news-room/fact-sheets/detail/maternal-mortality. 3. Rodríguez-Angulo E, Aguilar-Pech P, Montero-Cervantes L, Hoil-Santos J,
Andueza-Pech G. Demoras en la atención de complicaciones maternas asociadas a fallecimientos en municipios del sur de Yucatán, México. Revi Biomed.
2012;23(1):23-32.
4. Roberts JM, Druzin M, August PA, et al. ACOG Guidelines: Hypertension in Pregnancy.; 2012. doi:doi: 10.1097/01.AOG.0000437382.03963.88
5. Revuelta, A.; Rodríguez, K.; Calderón B. Panorama Epidemiológico Y Mortalidad Por Causas Sujetas A Epidemiología En México. 2012.
https://www.gob.mx/cms/uploads/attachment/file/267615/Mortalidad_2012.pdf. 6. Revuelta, A.; Rodríguez, K.; Calderón B. Panorama Epidemiológico Y
Mortalidad Por Causas Sujetas A Epidemiología En México. 2015.
https://www.gob.mx/cms/uploads/attachment/file/307006/Mortalidad_2015.pdf. 7. Lindheimer MD, Taler SJ, Cunningham FG. Hypertension in pregnancy. J Am
Soc Hypertens. 2010;4(2):68-78. doi:10.1016/j.jash.2010.03.002
8. ACOG Committee on Obstetric Practice. Practice bulletin #33: diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99(1):159- 167. doi:10.1016/S0029-7844(01)01747-1
9. Stone P, Cook D, Hutton J, Purdie G, Murray H, Harcourt L. Measurements of blood pressure, oedema and proteinuria in a pregnant population of New Zealand. Aust N Z J Obstet Gynaecol. 1995;35(1):32-37.
http://www.ncbi.nlm.nih.gov/pubmed/7771996.
10. Roccella EJ. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol. 2000;183(1):S1-S22. doi:10.1067/mob.2000.107928
11. Kuo VSp and its assessment in normal and hypertensive pregnancy., Koumantakis G, Gallery ED. Proteinuria and its assessment in normal and hypertensive pregnancy. Am J Obstet Gynecol. 1992;167(3):723-728. http://www.ncbi.nlm.nih.gov/pubmed/1530030.
12. Homer CS, Brown MA, Mangos G, Davis GK. Non-proteinuric pre-eclampsia: a novel risk indicator in women with gestational hypertension. J Hypertens. 2008;26(2):295-302. doi:10.1097/HJH.0b013e3282f1a953
13. Morikawa M, Yamada T, Yamada T, et al. Pregnancy outcome of women who developed proteinuria in the absence of hypertension after mid-gestation. J Perinat Med. 2008;36(5). doi:10.1515/JPM.2008.062
14. Caritis S, Sibai B, Hauth J, et al. Low-Dose Aspirin to Prevent Preeclampsia in Women at High Risk. N Engl J Med. 1998;338(11):701-705.
doi:10.1056/NEJM199803123381101
15. Fisher KA, Luger A, Spargo BH, Lindheimer MD. Hypertension in pregnancy: clinical-pathological correlations and remote prognosis. Medicine (Baltimore). 1981;60(4):267-276. http://www.ncbi.nlm.nih.gov/pubmed/7242320.
significantly higher in severe gestational hypertension than in mild preeclampsia. Am J Obstet Gynecol. 2002;186(1):66-71.
http://www.ncbi.nlm.nih.gov/pubmed/11810087.
17. Williams D. Long-Term Complications of Preeclampsia. Semin Nephrol. 2011;31(1):111-122. doi:10.1016/j.semnephrol.2010.10.010
18. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.
doi:10.1136/bmj.38380.674340.E0
19. Poon LCY, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010;24(2):104-110. doi:10.1038/jhh.2009.45
20. George EM, Granger JP. Endothelin: Key Mediator of Hypertension in Preeclampsia. Am J Hypertens. 2011;24(9):964-969. doi:10.1038/ajh.2011.99 21. Roberts JM, Hubel CA. The Two Stage Model of Preeclampsia: Variations on
the Theme. Placenta. 2009;30:32-37. doi:10.1016/j.placenta.2008.11.009 22. Nnabuike C. Ngene JM. Role of angiogenic factors in the pathogenesis and
management of pre-eclampsia. Int J Gynecol Obstet. 2018;141(1):5-13. doi:https://doi.org/10.1002/ijgo.12424
23. Maynard SE, Karumanchi SA. Angiogenic Factors and Preeclampsia. Semin Nephrol. 2011;31(1):33-46. doi:10.1016/j.semnephrol.2010.10.004
24. Powe CE, Levine RJ, Karumanchi SA. Preeclampsia, a Disease of the Maternal Endothelium: The Role of Antiangiogenic Factors and Implications for Later Cardiovascular Disease. Circulation. 2011;123(24):2856-2869.
doi:10.1161/CIRCULATIONAHA.109.853127
25. Xu Y, Shen M, Jin A, Li H, Zhu R. Maternal circulating levels of transforming growth factor-β superfamily and its soluble receptors in hypertensive disorders of pregnancy. Int J Gynecol Obstet. 2017;137(3):246-252. doi:10.1002/ijgo.12142 26. Naljayan M V., Karumanchi SA. New Developments in the Pathogenesis of
Preeclampsia. Adv Chronic Kidney Dis. 2013;20(3):265-270. doi:10.1053/j.ackd.2013.02.003
27. Palei AC, Spradley FT, Warrington JP, George EM, Granger JP.
Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology. Acta Physiol. 2013;208(3):224-233. doi:10.1111/apha.12106 28. O’Gorman N, Wright D, Poon LC, et al. Accuracy of competing-risks model in
screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks’ gestation. Ultrasound Obstet Gynecol. 2017;49(6):751-755.
doi:10.1002/uog.17399
29. Kenny LC, Black MA, Poston L, et al. Early Pregnancy Prediction of
Preeclampsia in Nulliparous Women, Combining Clinical Risk and Biomarkers: The Screening for Pregnancy Endpoints (SCOPE) International Cohort Study. Hypertension. 2014;64(3):644-652.
doi:10.1161/HYPERTENSIONAHA.114.03578
30. Sircar M, Thadhani R, Karumanchi SA. Pathogenesis of preeclampsia. Curr Opin Nephrol Hypertens. 2015;24(2):131-138. doi:10.1097/MNH.0000000000000105 31. Chaiworapongsa T, Chaemsaithong P, Yeo L, Romero R. Pre-eclampsia part 1:
current understanding of its pathophysiology. Nat Publ Gr. 2014;10(10):466-480. doi:10.1038/nrneph.2014.102
and Eclampsia.; 2011. doi:NBK140561 [bookaccession]
33. Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: A systematic review and meta-analysis. Fetal Diagn Ther. 2012;31(3):141-146. doi:10.1159/000336662 34. Hofmeyr GJ, Lawrie TA, Atallah AN, Duley L, Torloni MR. Calcium
supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane database Syst Rev. 2014;6:CD001059.
doi:10.1002/14651858.CD001059.pub4
35. Organisation WH. WHO | Calcium supplementation in pregnant women. WHO | Calcium supplementation in pregnant women.
http://www.who.int/nutrition/publications/micronutrients/guidelines/calcium_sup plementation/en/. Published 2013.
36. Peres G, Mariana M, Cairrão E. Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal. J Cardiovasc Dev Dis.
2018;5(1):3. doi:10.3390/jcdd5010003
37. National Collaborating Centre for Women’s Health and Children’s, National Institute for Health and Clinical Excellence. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy.; 2010.
38. Moussa HN, Arian SE, Sibai BM. Management of Hypertensive Disorders in Pregnancy. Women’s Heal. 2014;10(4):385-404. doi:10.2217/WHE.14.32 39. Podymow T, August P. Antihypertensive Drugs in Pregnancy. Semin Nephrol.
2011;31(1):70-85. doi:10.1016/j.semnephrol.2010.10.007
40. Bouet PE, Brun S, Madar H, et al. Implementation of an antenatal magnesium sulfate protocol for fetal neuroprotection in preterm infants. Sci Rep. 2015;5. doi:10.1038/srep14732
41. Fong A, Chau CT, Pan D, Ogunyemi DA. Clinical morbidities, trends, and demographics of eclampsia: A population-based study. Am J Obstet Gynecol. 2013;209(3):229.e1-229.e7. doi:10.1016/j.ajog.2013.05.050
42. Shao Y, Qiu J, Huang H, et al. Pre-pregnancy BMI, gestational weight gain and risk of preeclampsia: A birth cohort study in Lanzhou, China. BMC Pregnancy Childbirth. 2017;17(1):2-9. doi:10.1186/s12884-017-1567-2
43. Salako BL, Odukogbe ATA, Olayemi O, et al. Serum albumin, creatinine, uric acid and hypertensive disorders of pregnancy. East Afr Med J. 2003;80(8):424- 428.
44. Wiles K, Bramham K, Seed PT, Nelson-Piercy C, Lightstone L, Chappell LC. Serum Creatinine in Pregnancy: A Systematic Review. Kidney Int Reports. 2019;4(3):408-419. doi:10.1016/j.ekir.2018.10.015
45. Sibai BM, Ramadan MK, Ihab U, Salama M. Maternal morbidity and mortality in 442 pregnancies with hemolysis , elevated liver enzymes , and low platelets ( HELLP syndrome ). 1993:1000-1006. doi:10.1016/0002-9378(93)90043-I
46. Chaturvedi S, Mccrae KR. 43 - Thrombocytopenia in Pregnancy. 4th ed. Elsevier Inc.; 2019. doi:10.1016/B978-0-12-813456-6.00043-6
47. Tamargo J, Caballero R, Delpón E. Pharmacotherapy for hypertension in pregnant patients: special considerations. Expert Opin Pharmacother. 2019;20(8):963-982. doi:10.1080/14656566.2019.1594773
48. Nabi S. Original Research Paper Gynecology ARE LOWERED BLOOD PLATELET COUNTS AN INDICATION OF HYPERTENSION AMONG PREGNANT WOMEN ? ABSTRACT DGO , DNB ( Obstetrics and Gynecology
), Senior resident , Civil Hospital , Gurgaon. 2019;(2):2-3.
49. Klajnbard A, Szecsi PB, Colov NP, et al. Laboratory reference intervals during pregnancy, delivery and the early postpartum period. Clin Chem Lab Med. 2010;48(2):237-248. doi:10.1515/CCLM.2010.033
50. El-Nafaty AU, Melah GS, Massa AA, Audu BM, Nelda M. The analysis of eclamptic morbidity and mortality in the Specialist Hospital Gombe, Nigeria. J Obstet Gynaecol (Lahore). 2004;24(2):142-147.
doi:10.1080/01443610410001645415
51. Scantlebury DC, Schwartz GL, Acquah LA, Moser M, Garovic VD. The Treatment of Hypertension During Pregnancy: When Should Blood Pressure Medications Be Started? Curr Cardiol Rep. 2014;15(11):1-17.